Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann; BIG 1-98 Collaborative Group

doi:10.1016/S1470-2045(11)70270-4

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Meredith M Regan, Patrick Neven, Anita Giobbie-Hurder, Aron Goldhirsch, Bent Ejlertsen, Louis Mauriac, John F Forbes, Ian Smith, István Láng, Andrew Wardley, Manuela Rabaglio, Karen N Price, Richard D Gelber, Alan S Coates, Beat Thürlimann, BIG 1-98 Collaborative Group

375 Citationer (Scopus)

Abstract

Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.

Originalsprog	Engelsk
Tidsskrift	Lancet Oncology
Vol/bind	12
Udgave nummer	12
Sider (fra-til)	1101-8
Antal sider	8
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(11)70270-4
Status	Udgivet - nov. 2011

Adgang til dokumentet

10.1016/S1470-2045(11)70270-4

Fingeraftryk

Dyk ned i forskningsemnerne om 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & BIG 1-98 Collaborative Group (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncology, 12(12), 1101-8. https://doi.org/10.1016/S1470-2045(11)70270-4

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. / Regan, Meredith M; Neven, Patrick; Giobbie-Hurder, Anita et al.
I: Lancet Oncology, Bind 12, Nr. 12, 11.2011, s. 1101-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Regan, MM, Neven, P, Giobbie-Hurder, A, Goldhirsch, A, Ejlertsen, B, Mauriac, L, Forbes, JF, Smith, I, Láng, I, Wardley, A, Rabaglio, M, Price, KN, Gelber, RD, Coates, AS, Thürlimann, B & BIG 1-98 Collaborative Group 2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up', Lancet Oncology, bind 12, nr. 12, s. 1101-8. https://doi.org/10.1016/S1470-2045(11)70270-4

@article{44877615fd2c4dee83f688b577dd7344,

title = "Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up",

abstract = "Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Australia, Breast Neoplasms, Cross-Over Studies, Disease-Free Survival, Double-Blind Method, Europe, Female, Humans, Kaplan-Meier Estimate, Neoplasm Recurrence, Local, Neoplasms, Second Primary, New Zealand, Nitriles, North America, Postmenopause, Proportional Hazards Models, Receptors, Steroid, Risk Factors, Selective Estrogen Receptor Modulators, South Africa, South America, Tamoxifen, Time Factors, Treatment Outcome, Triazoles, Tumor Markers, Biological",

author = "Regan, {Meredith M} and Patrick Neven and Anita Giobbie-Hurder and Aron Goldhirsch and Bent Ejlertsen and Louis Mauriac and Forbes, {John F} and Ian Smith and Istv{\'a}n L{\'a}ng and Andrew Wardley and Manuela Rabaglio and Price, {Karen N} and Gelber, {Richard D} and Coates, {Alan S} and Beat Th{\"u}rlimann and {BIG 1-98 Collaborative Group}",

year = "2011",

month = nov,

doi = "10.1016/S1470-2045(11)70270-4",

language = "English",

volume = "12",

pages = "1101--8",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

AU - Regan, Meredith M

AU - Neven, Patrick

AU - Giobbie-Hurder, Anita

AU - Goldhirsch, Aron

AU - Ejlertsen, Bent

AU - Mauriac, Louis

AU - Forbes, John F

AU - Smith, Ian

AU - Láng, István

AU - Wardley, Andrew

AU - Rabaglio, Manuela

AU - Price, Karen N

AU - Gelber, Richard D

AU - Coates, Alan S

AU - Thürlimann, Beat

AU - BIG 1-98 Collaborative Group

PY - 2011/11

Y1 - 2011/11

N2 - Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.

AB - Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Aromatase Inhibitors

KW - Australia

KW - Breast Neoplasms

KW - Cross-Over Studies

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Europe

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Neoplasm Recurrence, Local

KW - Neoplasms, Second Primary

KW - New Zealand

KW - Nitriles

KW - North America

KW - Postmenopause

KW - Proportional Hazards Models

KW - Receptors, Steroid

KW - Risk Factors

KW - Selective Estrogen Receptor Modulators

KW - South Africa

KW - South America

KW - Tamoxifen

KW - Time Factors

KW - Treatment Outcome

KW - Triazoles

KW - Tumor Markers, Biological

U2 - 10.1016/S1470-2045(11)70270-4

DO - 10.1016/S1470-2045(11)70270-4

M3 - Journal article

C2 - 22018631

SN - 1470-2045

VL - 12

SP - 1101

EP - 1108

JO - Lancet Oncology

JF - Lancet Oncology

IS - 12

ER -